Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2016 - 2026)

Zevra Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $65.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 42.95% year-over-year to $65.9 million; the trailing twelve-month figure through Mar 2026 stood at $65.9 million (down 42.95% YoY), and the FY2025 full-year result was $128.4 million, down 4.09% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $65.9 million, down from $128.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $135.7 million in Q2 2025, with the low at $5.9 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $74.0 million across 5 years, with a median of $93.9 million in 2024.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 85.85% — and 2024, when it soared 1854.61%.
• Zevra Therapeutics' Total Non-Current Liabilities stood at $40.2 million in 2022, then soared by 174.82% to $110.5 million in 2023, then rose by 21.15% to $133.8 million in 2024, then dropped by 4.09% to $128.4 million in 2025, then tumbled by 48.66% to $65.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $65.9 million (Q1 2026), $128.4 million (Q4 2025), and $119.5 million (Q3 2025), per Business Quant data.